SPIRIT Study FVIII Tolerance Hemophilia A Children
Summary
The NIH has registered the SPIRIT observational cohort study (NCT07539402) investigating immunological tolerance mechanisms to clotting factor VIII (FVIII) in children under 18 years with congenital hemophilia A who are using Non-Factor Therapy prophylaxis. The study seeks to understand how robust FVIII tolerance is in patients with infrequent FVIII exposure enabled by NFT. Findings may inform clinical understanding of inhibitor development risk but do not alter current treatment standards or create compliance obligations.
“Children with hemophilia A lack clotting factor VIII (FVIII) due to a genetic mutation.”
What changed
The NIH registered a new observational cohort study titled 'Searching Patterns In the Robustness of Immunological FVIII Tolerance' (SPIRIT) on ClinicalTrials.gov. The study will investigate immunological tolerance mechanisms in children under 18 years with congenital hemophilia A who use Non-Factor Therapy for prophylaxis, examining how the infrequent FVIII exposure enabled by effective NFT prevention affects pre-existing tolerance.
The study registration represents routine clinical research documentation without regulatory or compliance implications. Clinical investigators and pharmaceutical companies involved in hemophilia therapeutics may monitor SPIRIT findings for potential insights into inhibitor development, but the registration itself does not create any new obligations, reporting requirements, or compliance deadlines for affected parties.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Searching Patterns In the Robustness of Immunological FVIII Tolerance
Observational NCT07539402 Kind: OBSERVATIONAL Apr 20, 2026
Abstract
Children with hemophilia A lack clotting factor VIII (FVIII) due to a genetic mutation. It is well known that administration of FVIII concentrate leads to immunological tolerance for the FVIII protein in the majority of children. In 30% of these children tolerance is not achieved leading to the development of anti-FVIII antibodies (i.e. inhibitors). Our knowledge on the underlying immunological mechanisms leading to tolerance is limited. Recently, Non-Factor Therapy (NFT) has become available for prevention of bleeding in patients with hemophilia, i.e. prophylaxis. Currently, many children with severe hemophilia A use NFT as the subcutaneous administration of NFT is very convenient. In children on NFT prophylaxis, intravenous FVIII concentrate is exclusively used on-demand for treatment of bleeding. As NFT is very effective in the prevention of bleeds, patients may not be exposed to the deficient FVIII protein for periods up to a year or longer. It is currently not known how robust immunological tolerance is in the absence of exposure to a deficient antigen. The infrequent exposure to FVIII, enabled by NFT, provides an opportunity to study the immunological tolerance mechanisms for FVIII in children with hemophilia A.
The aim of SPIRIT is to investigate the mechanisms of the immunological tolerance to FVIII in patients with hemophilia A aged younger than 18 years using NFT for prophylaxis.
In this observational cohort study, children (aged <18 years) with congenital hem...
Conditions: Hemophilia A, Hemophilia A, Congenital
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.